Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Recursion on the deal. Recursion, a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
You must be a Standard 1 Year member to access this content.
Sheppard Mullin and Winston & Strawn served as counsel to Alkuri Global Acquisition Corp. on the deal. Freshfields advised Dr. Ali Parsa, Founder, CEO and major...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Pinsent Masons advised 4D pharma plc on the deal. 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk advised the representatives of the underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
